Know Cancer’s Next Move

How do you guide treatment decisions when next steps are unclear?

Signatera™ Molecular Residual Disease (MRD) Assay is a highly sensitive and custom designed test, using circulating tumor DNA (ctDNA) to help inform treatment decisions.

Learn More

Informing treatment decisions along the continuum of care

Use Signatera™ after surgery to evaluate the need for adjuvant chemotherapy.

Use Signatera™ alongside CEA and imaging to detect recurrence earlier.

3-assess-a-patient-response-to-treatment

Assess a patient’s response to treatment in the neoadjuvant, adjuvant or immunotherapy settings.

Identify high risk patients with progressive disease who may benefit from earlier intervention or additional imaging.

Clinical applications of ctDNA testing

Natera presentations at 2024 European Society for Medical Oncology

In partnership with our collaborators, Natera is proud to be presenting exciting new data at the 2024 European Society for Medical Oncology, further validating the use of tumor-informed ctDNA analysis to advance the care for patients with solid tumor cancers. See accepted data below to be presented at the annual meeting.

Saturday September 14, 2024

Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN

Abstract ID: 923P

Natasha Honoré

Brussels, Belgium

Monday September 16, 2024

Association Between Copy Number Aberration and ctDNA MRD in Colorectal Cancer: CIRCULATE-Japan GALAXY

Abstract ID: 555P

Tomoya Harima

Fukuoka, Japan
HIBRID: Histology and ctDNA based Risk-stratification with Deep Learning

Abstract ID: 545P

Chiara M. Loeffler

Dresden, Germany
Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY

Abstract ID: 553P

Jun Nagata

Kitakyushu, Japan

Novel Clinical Decision Support (CDS) System Optimizing Adjuvant Chemotherapy (ACT) for Colorectal Cancer (CRC) by Integrating Deep Learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY Histotyping

Abstract ID: 554P

Yoshiaki Nakamura

Kashiwa, Japan, Chiba
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases; subgroup analysis from CIRCULATE-Japan GALAXY

Abstract ID: 558P

Kozo Kataoka

Nishinomiya, Japan
The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients

Abstract ID: 314P

Mark Magbanua

San Francisco, United States of America

EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)

Abstract ID: 338TiP

Michail Ignatiadis

Brussels, Belgium

What is the significance of the data from ASCO GI?

The presence of post-surgical ctDNA has been shown to be the most significant prognostic factor and reinforces the predictive value of adjuvant chemotherapy (ACT).

ESMO 2023: ctDNA positive patients who received ACT had significantly higher DFS at 24 months compared to those with no ACT (38.6% v. 16.1%, p-value <0.01)
ASCO GI 2024: ctDNA positive pts with sustained ctDNA clearance after ACT were significantly associated with >90% DFS. For patients with transient clearance who ultimately recurred clinically or radiographically, 98% experienced molecular recurrence by 18 months
By analyzing the duration of clearance, we validate the power of serial testing: patients who clear their ctDNA has been shown to be a strong indicator of disease-free survival (DFS)

Fine tuning chemotherapy

As we have seen in the recently presented data, patients who do not clear their ctDNA are at an increased risk of recurrence. Listen in how one providers incorporates Signatera™ into to his practice with the goal to impact patient care.

Tracks Disease Burden Over Time via ctDNA Dynamics

Signatera™ is designed to accurately detect residual disease with an ultra-low level of detection (0.01% MTM/mL)
Real time ctDNA analysis can help inform important adjuvant therapy decisions
Signatera™ can also track ctDNA dynamics so you can gain real-time insight of disease burden.

Facilitating shared-decision making

Listen in to Keith’s incredible story about how he and his provider used Signatera™ to help inform next steps in his treatment journey.

Is Signatera right for your patients?

We’re here to help you find out

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019.

²Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019;25(14):4255-4263.

³Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.

⁴Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547-1557.

⁵Kotani D. et al., Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer, Nature Medicine v29 Issue 1 Jan 2023